News
Release
FOR IMMEDIATE RELEASE
November 16, 2006
Contact: Michelle Deaver
Number: (214) 366-6963
Lead
Defendant In Health Care Fraud and
Rogue Internet Pharmacy Scheme Pleads Guilty
NOV 16 --
(DALLAS) – Yesterday, in U.S. District Court in Dallas before
United States Magistrate Judge Irma C. Ramirez, lead defendant Rakesh
Jyoti Saran pleaded guilty to one count of conspiracy to commit health
care fraud and other federal offenses; two counts of mail fraud; and
one count of conspiracy to distribute controlled substances, announced
United States Richard B. Roper. Saran, age 44, of Arlington, Texas,
faces a statutory maximum sentence of twenty years imprisonment. He
will be scheduled for sentencing by U.S. District Judge Jorge A. Solis.
Saran was arrested
on September 21, 2005 on charges outlined in a 201-count federal indictment
alleging that from November 1999 through September 20, 2005 he and
the codefendants conspired with each other and others to commit health
care fraud, wire fraud, mail fraud, and money laundering and to engage
in the illegal distribution of controlled substances in a drug diversion
scheme.
“The conviction
of Rakesh Jyoti Saran and his co-conspirators, along with the forfeiture
of their ill gotten gains should demonstrate the governments resolve
in targeting, arresting and prosecuting those individuals involved
in the illegal distribution of pharmaceutical drugs over the internet,” said
Special Agent in Charge, James L. Capra of the Dallas Division of the
DEA. “This partnership of local, state and federal agencies nationwide
lead to the dismantling of this internet trafficking organization.
This was an extremely complex undertaking and all agencies, investigators
and prosecutors should be commended for their perseverance and dedication
to duty.”
Based on plea papers
filed yesterday, Saran operated twenty-three Texas-incorporated pharmacies
through two companies owned by him, Carrington Healthcare Systems,
Inc. and Infinity Services Group, Inc., and purchased expensive pharmaceuticals
at significant discounts from pharmaceutical wholesale suppliers, including
AmerisourceBergen, located in Valley Forge, Pennsylvania; Anda, Inc.,
located in Florida; Cardinal Health, located in Dublin, Ohio; H.D.
Smith, located in Fort Worth, Texas; and Morris & Dickson Co.,
L.L.C. in Shreveport, Louisiana. Saran’s pharmacies purchased
controlled substances such as hydrocodone (an addictive painkiller),
phentermine hydrochloride (an appetite suppressant), alprazolam (used
to treat anxiety, depression, panic disorder and premenstrual syndrome),
and promethazine cough syrup (containing codeine) and obtained significant
price discounts by obtaining fraudulent memberships in Group Purchasing
Organizations (GPOs). To qualify for the significantly discounted “contract
pricing” available to GPOs, Saran fraudulently represented to
wholesale suppliers that his purchases were for “institutional
distribution” and signed contracts containing “own use” or “closed
door pharmacy” provisions restricting his distribution of the
pharmaceuticals to institutions such as prisons, long-term care facilities,
and rehabilitation hospitals. However, Saran sold the significantly-discounted
pharmaceuticals outside the scope of the provisions, making substantial
profits from the diverted transactions. Saran did not disclose to the
wholesalers that the pharmacies were alter ego businesses he had created
and that he had obtained individual DEA registration numbers for each
one to camouflage his identity as the actual purchaser.
Saran also utilized
his pharmacies to operate a “store front” website designed
to facilitate the distribution of controlled substances to internet
customers. Using the website, drug users illegally acquired controlled
substances and dangerous drugs without valid prescriptions and without
doctor intervention, paying up to four times the cost if the substances
had been acquired legally.
Saran also used
his pharmacies to fill pharmaceutical order from other Internet Facilitation
Centers (IFC) involved in the illegal distribution of dangerous drugs
and controlled substances. Additionally, Saran also played an integral
role in providing promethazine cough syrup with codeine, hydrocodone,
and alprazolam to individuals who illegally sold these drugs “on
the street”, acquiring approximately $20 million in proceeds
for doing so.
As part of his plea
agreement, Saran will forfeit assets earned from his illegal activities,
including over $1,000,000 in cash seized at his residence; more than
$375,000 found in bank accounts; several vehicles; and a custom home
under construction in Arlington.
In addition to his
own guilty plea, Saran entered guilty pleas on behalf of twenty corporations
he controlled and used in the criminal conspiracy, including Alliance
Pharmacy Services, Inc.; AMS Pharmaceuticals Group, Inc.; Carrington
Health Care System, Inc.; Dalamar Services, Inc.; East Pointe Pharmacy
Services, Inc.; Everest Services, Inc.; Infiniti Services Group, Inc.;
Med-Care Infusion Services, Inc.; National Executive Management, Inc.;
Orion Pharmacy Services, Inc.; Precision Pharmacy Services, Inc.; Premium
Pharmacy Services, Inc.; Quantum Infusion, Inc.; Reliance Pharmaceutical,
Inc.; Southwest Infusion, Inc.; SWS Pharmacy Services, Inc.; Texas
Home Infusion, L.L.C.; Tri-Phasic Pharmacy, Inc.; Trinity Infusion
Services, Inc.; and Trinity Pharmacy Services, Inc.
Sixteen other defendants,
including managers and employees of Saran’s various pharmacies,
have also pleaded guilty to charges in the indictment, including conspiracy
to commit healthcare fraud and conspiracy to distribute controlled
substances.
U.S. Attorney Roper
said, “These convictions show that Internet Pharmacies who illegally
peddle controlled substances over the internet will be brought to justice.
Saran’s multimillion dollar nationwide operation was successfully
dismantled by the hard work and cooperation of federal, state and local
law enforcement. These successful convictions should exemplify federal
and local law enforcement’s commitment to address this serious
problem of rouge on line pharmacy.”
U.S. Attorney Roper
especially recognized the investigative efforts and teamwork of the
U.S. Food and Drug Administration - Office of Criminal Investigations;
Federal Bureau of Investigation; Drug Enforcement Administration; Internal
Revenue Service – Criminal Investigation; U.S. Department Social
Security Administration - Office of the Inspector General; U.S. Department
of Veteran Affairs - Office of the Inspector General; Texas Department
of State Health Services and the Texas State Board of Pharmacy.
|